Charles L. Loprinzi, MD, on Olanzapine for Prevention of CINV
2015 Palliative Care in Oncology SymposiumCharles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Related Videos
Lawrence H. Einhorn, MD, on CINV Clinical Trial Results: The Alliance A221301 Study
Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomitin...
Jennifer S. Temel, MD's Expert Perspective: Palliative Care in 2015
As Steering Committee Chair of this year’s symposium, Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses the goals and highlights of the meeting.
Judith Vick, MD Candidate, and Rachelle E. Bernacki, MD, on A New Clinical Tool: The “Surprise Question”
Judith Vick, MD Candidate, of Johns Hopkins University School of Medicine, and Rachelle E. Bernacki, MD, of Dana-Farber Cancer Institute, discuss a tool that could...
Kathleen Elizabeth Bickel, MD, MPhil, on Defining High-Quality Palliative Care in Oncology Practice
Kathleen Elizabeth Bickel, MD, MPhil, of the White River Junction VA Medical Center, discusses the ASCO/AAHPM Guidance Statement, which will help oncology providers enhance their d...
Eduardo Bruera, MD, on Cachexia Assessment and Management State of the Art
Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerg...
